Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Settings

Author: search.filters.author.Ivanov, EmilijaSubject: search.filters.subject.CYP2B6 gene

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    EFFECT OF CYP2B6 POLYMORPHISM ON PROPOFOL IN PATIENTS UNDERGOING ABDOMINAL HYSTERECTOMY
    (Department of Anaesthesia and Reanimation, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, R.N. Macedonia, 2022-03)
    Ivanov, Emilija
    ;
    ;
    ;
    ;
    Krstevska, Jasmina
    Understanding why individuals respond differently to drug therapy is one of the most intriguing questions in modern medicine and pharmacology. The main premise is that individual differences in genetic variables in genes encoding metabolic enzymes, molecular transporters and propofol molecular binding sites are implicated in the sensitivity to the effects of propofol, a commonly used intravenous anesthetic. The goal of this research was to see how polymorphisms in the cytochrome P450 2B6 isozyme CYP2B6 gene impacted the propofol therapeutic outcomes in patients subjected to abdominal hysterectomy. This study included ninety patients ranging in age from 29 to 74 years old and from various ethnic backgrounds. TaqMan SNP genotyping analysis on Stratagene MxPro 3005P real-time polymerase chain reaction was used to determine the presence of polymorphisms (qPCR). The genetic variations were distributed inside the Hardy-Weinberg equilibrium. The allelic frequencies of polymorphic variations and genotype distributions across adult and elderly patients, as well as patients of different ethnicities, were not significantly different (p>0.05). According to our findings, the CYP2B6 gene variations did not cause any statistically significant effects on the analyzed clinical parameters i.e., doses for induction in anesthesia, additional doses, induction time and awakening time after anesthesia and adverse effects of propofol.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    INFLUENCE OF POTENTIAL GENE POLYMORPHISMS ON PROPOFOL DOSAGE REGIMEN IN PATIENTS UNDERGOING ABDOMINAL HYSTERECTOMY
    (Macedonian Academy of Sciences and Arts, 2021)
    Ivanov, Emilija
    ;
    ;
    Budic, Ivana
    ;
    Nojkov, Jordan
    ;
    Propofol (2,6-diisopropylphenol) is the most common intravenous anesthetic used in modern medicine. It is postulated that individual differences in genetic factors [polymorphism of single nucleotide polymorphisms (SNPs)] in the genes encoding metabolic enzymes, molecular targets and molecular binding sites of propofol can be responsible for susceptibility to propofol effects. The aim of our study was to investigate the influence of the cytochrome P450 2B6 isozyme CYP2B6 (rs3745274), γ-aminobutyric acid type A (GABAA) receptor α1 subunit GABRA1 (rs2279020) and ATP-binding cassette subfamily B member 1 ABCB1 (rs1045642) gene polymorphisms on propofol therapeutic outcomes in the patients undergoing abdominal hysterectomy. Ninety patients aged 29-74 years, with different ethnicities were included in this study. The presence of polymorphisms was analyzed using TaqMan SNP genotype analysis on Stratagene MxPro 3005P real-time polymerase chain reaction (qPCR). The distribution of all three genetic variants was within the Hardy-Weinberg equilibrium. There was no significant difference (p >0.05) in the allelic frequencies of polymorphic variants and genotype distributions between adult and older patients and between patients of different ethnicities. Our study did not detect a statistically significant influence of the CYP2B6 (c.516G>A), GABRA1 (c.1059+15G>A) and ABCB1 (c.3435T>C) variants on the variability of clinical parameters (doses for induction in anesthesia, additional doses, induction time and wake time after anesthesia and side effects of propofol). However, the observed trend on the possible influence of the CYP2B6 (c.516G>A) and GABRA1 (c.1059+15G>A) variants warrant an extension of these studies on a larger number of patients.